naltrexone has been researched along with Chronic Disease in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (12.07) | 18.7374 |
| 1990's | 10 (17.24) | 18.2507 |
| 2000's | 21 (36.21) | 29.6817 |
| 2010's | 14 (24.14) | 24.3611 |
| 2020's | 6 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Agabio, R; Minozzi, S; Rösner, S; Saulle, R | 1 |
| Chadwick, AL; Rupp, A; Young, E | 1 |
| Conigrave, JH; Conigrave, KM; Lee, KSK; Purcell-Khodr, G; Vnuk, J | 1 |
| Creech, ZA; Koushik, SS; Noss, B; Poliwoda, S; Truong, GTD; Urits, I; Viswanath, O | 1 |
| Benth, JŠ; Fadnes, LT; Gaulen, Z; Kloster, PS; Kunøe, N; Opheim, A; Solli, KK; Tanum, L | 1 |
| Coffa, D; Snyder, H | 1 |
| Ghafoor, R; Kaleem, S; Khan, S | 1 |
| Ekelem, C; Juhasz, M; Khera, P; Mesinkovska, NA | 1 |
| Howland, RH | 1 |
| Schairer, J; Thapa, SD | 1 |
| Meyer, AC; Miller, ME; Sigmon, SC | 1 |
| Reece, AS | 1 |
| Hervera, A; Leánez, S; Negrete, R; Pol, O | 1 |
| Johnson, F; Katz, N; Stauffer, J; Sun, S | 1 |
| Bernhard, JD; Luger, TA; Phan, NQ; Ständer, S | 1 |
| Belavic, JM | 1 |
| Johnson, BA | 1 |
| Hale, M; Katz, N; Morris, D; Stauffer, J | 1 |
| Brewer, R; Johnson, FK; Morris, D; Sekora, D; Stauffer, J; Wang, C; Webster, LR | 1 |
| Iyer, SS; Manley, AL; Randazzo, BP; Schulman, SL; Tzanis, EL; Wang, W; Zhang, H | 1 |
| Hesselink, JM; Kopsky, DJ | 1 |
| Cancela, LM; del Rosario, CN; Pacchioni, AM | 1 |
| Lubin, G; Shmushkevitz, M; Valevski, A; Weizman, A | 1 |
| Kuraishi, Y; Maekawa, T; Nojima, H; Yamaguchi-Miyamoto, T | 1 |
| Liu, HX | 1 |
| O'Brien, CP | 2 |
| Kaneko, C; Kuzumaki, N; Matsuzawa, K; Miyoshi, K; Nagumo, Y; Nakajima, M; Nanjo, K; Narita, M; Suzuki, T; Yamazaki, M | 1 |
| Hareyama, N; Kaneko, C; Kuzumaki, N; Miyatake, M; Miyoshi, K; Nagumo, Y; Nakajima, M; Narita, M; Sato, F; Seyama, Y; Shindo, K; Suzuki, T; Wachi, H | 1 |
| Beheshtian, A; Dehpour, AR; Ghahremani, MH; Kiumehr, S; Payabvash, S; Sabzevari, O; Salmasi, AH; Tavangar, SM | 1 |
| McKay, JR | 1 |
| Kordik, CP; Levin, ED; Overstreet, DH; Reitz, AB; Rezvani, AH; Rosenthal, DI; Vaidya, AH | 1 |
| Anvari, P; Dehpour, AR; Kiumehr, S; Nezami, BG; Payabvash, S; Tavangar, SM; Zandieh, A | 1 |
| Crain, SM; Shen, KF | 1 |
| Hamabe, W; Mashida, E; Nagae, R; Tokuyama, S | 1 |
| Arout, CA; Inturrisi, CE; Juni, A; Kest, B; Klein, G; Waxman, AR | 1 |
| Tyndale, R | 1 |
| Azad, SC; Beyer, A; Huge, V; Rammes, G; Zieglgänsberger, W | 1 |
| Ban, T; Berney, S; Ragheb, M | 1 |
| Chelli, F; Cotani, P; Giordano, A; Marchesi, GF; Santone, G | 2 |
| Kolta, MG; Ngong, JM; Pierzchala, K; Rutledge, LP; Van Loon, GR | 1 |
| Hao, JX; Xu, XJ; Yu, W | 1 |
| Manara, AR; Merriman, RJ; Mills, IH; Park, GR | 1 |
| Kishimoto, Y; Misawa, M; Nagase, H; Suzuki, T; Takeda, F | 1 |
| Gumułka, SW; Kolaric, S; Makulska-Nowak, HE; Mizerska, K | 1 |
| Ko, SM | 1 |
| Dekker, LR; Jones, EA | 1 |
| Brandão, ML; Cuadra, G; Martijena, I; Molina, V; Zurita, A | 1 |
| Kaneko, M; Kawakita, T; Kuraishi, Y; Maekawa, T; Miyamoto, T; Nishikawa, Y; Nojima, H; Yamaguchi, T | 1 |
| Cancela, LM; del Rosario Capriles, N | 1 |
| Mackay, AV | 1 |
| McNamee, HB; Meyer, RE; Mirin, SM | 1 |
| Monroe, EW | 1 |
| Bamford, CR; Sandyk, R | 1 |
| Kinzie, J; Luby, ED; Marrazzi, MA | 1 |
| Girardot, MN; Holloway, FA | 1 |
11 review(s) available for naltrexone and Chronic Disease
| Article | Year |
|---|---|
Baclofen for alcohol use disorder.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone | 2023 |
Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review.
Topics: Chronic Disease; Chronic Pain; Humans; Inflammation; Naltrexone; Quality of Life | 2023 |
Opioid Use Disorder: Medical Treatment Options.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Evidence-Based Medicine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.
Topics: Administration, Oral; Administration, Topical; Chronic Disease; Dermatitis; Dermatitis, Atopic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Severity of Illness Index; Treatment Outcome; United States | 2019 |
A morphine/naltrexone combination (Embeda) for pain.
Topics: Analgesics, Opioid; Chronic Disease; Delayed-Action Preparations; Drug Approval; Drug Combinations; Humans; Morphine; Naltrexone; Narcotic Antagonists; Osteoarthritis; Pain; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2010 |
Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
Topics: Administration, Oral; Antipruritics; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Naloxone; Naltrexone; Pruritus; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2010 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult | 2010 |
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Narcotics; Prognosis; Recurrence; Risk Factors; Substance-Related Disorders; Taurine | 2003 |
Continuing care in the treatment of addictive disorders.
Topics: Alcoholism; Chronic Disease; Cognitive Behavioral Therapy; Continuity of Patient Care; Counseling; Humans; Naltrexone; Narcotic Antagonists; Retention, Psychology; Secondary Prevention | 2006 |
Treatment of alcoholism as a chronic disorder.
Topics: Adult; Alcoholism; Animals; Chronic Disease; Clinical Trials as Topic; Endorphins; Humans; Naltrexone; Patient Compliance; Recurrence | 1994 |
Under-diagnosed psychiatric syndrome. I: Trichotillomania.
Topics: Adolescent; Age of Onset; Alopecia; Antipsychotic Agents; Behavior Therapy; Child; Chronic Disease; Eyelashes; Female; Hair; Humans; Male; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sex Factors; Trichotillomania | 1999 |
14 trial(s) available for naltrexone and Chronic Disease
| Article | Year |
|---|---|
Low rates of prescribing alcohol relapse prevention medicines in Australian Aboriginal Community Controlled Health Services.
Topics: Acamprosate; Adult; Alcoholism; Australia; Australian Aboriginal and Torres Strait Islander Peoples; Chronic Disease; Disulfiram; Health Services, Indigenous; Humans; Male; Middle Aged; Naltrexone; Secondary Prevention | 2023 |
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2023 |
Efficacy of Low Dose Naltrexone in Psoriasis.
Topics: Adolescent; Adult; Chronic Disease; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Psoriasis; Quality of Life; Severity of Illness Index; Young Adult | 2020 |
Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.
Topics: Adult; Behavior Therapy; Buprenorphine; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Misuse | 2015 |
ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Illicit Drugs; Male; Middle Aged; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Treatment Outcome | 2010 |
Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Morphine; Naltrexone; Narcotic Antagonists; Osteoarthritis; Pain; Pain Measurement; Placebos; Treatment Outcome | 2010 |
Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Chronic Disease; Constipation; Delayed-Action Preparations; Drug Combinations; Female; Humans; Male; Middle Aged; Morphine; Naltrexone; Narcotic Antagonists; Nausea; Pain; Pain Measurement; Treatment Outcome | 2010 |
Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.
Topics: Analgesics, Opioid; Back Pain; Chronic Disease; Constipation; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds | 2011 |
Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.
Topics: Adult; Arousal; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Receptors, Opioid; Stress Disorders, Post-Traumatic; Treatment Outcome | 2002 |
Naltrexone in chronic schizophrenia. Results of a clinical trial.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Psychiatric Status Rating Scales; Schizophrenia | 1980 |
The therapeutic role of naltrexone in negative symptom schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1995 |
Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions.
Topics: Adult; Anesthetics, Dissociative; Anorexia; Chronic Disease; Compulsive Personality Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Ketamine; Memory; Naltrexone; Narcotic Antagonists; Treatment Outcome | 1998 |
Naltrexone in chronic negative schizophrenia.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Humans; Male; Naltrexone; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1992 |
Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis.
Topics: Chronic Disease; Dermatitis, Atopic; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Placebos; Pruritus; Random Allocation; Urticaria | 1989 |
33 other study(ies) available for naltrexone and Chronic Disease
| Article | Year |
|---|---|
The Utilization of Low Dose Naltrexone for Chronic Pain.
Topics: Analgesics, Opioid; Chronic Disease; Chronic Pain; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2023 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic | 2013 |
Narcotic-induced pain.
Topics: Abdominal Pain; Adult; Analgesics, Opioid; Anorexia; Chronic Disease; Diabetes Mellitus, Type 1; Drug Administration Schedule; Endoscopy, Gastrointestinal; Gastroparesis; Humans; Hypertension; Kidney Failure, Chronic; Male; Naltrexone; Narcotic Antagonists; Nausea; Neuralgia; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome; Treatment Outcome; Vomiting | 2015 |
Chronic ulcers caused by injection of substances: healing aided by naltrexone.
Topics: Chronic Disease; Diabetes Mellitus, Type 1; Drug Implants; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Skin Ulcer; Substance Abuse, Intravenous; Wound Healing | 2009 |
The peripheral administration of a nitric oxide donor potentiates the local antinociceptive effects of a DOR agonist during chronic inflammatory pain in mice.
Topics: Analgesics, Opioid; Animals; Chronic Disease; Disease Models, Animal; Drug Therapy, Combination; Enkephalin, D-Penicillamine (2,5)-; Freund's Adjuvant; Hot Temperature; Hyperalgesia; Inflammation; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Pain Measurement; Receptors, Opioid, delta; Time Factors | 2009 |
New drug formulation treats chronic pain.
Topics: Analgesics, Opioid; Chemistry, Pharmaceutical; Chronic Disease; Drug Combinations; Drug Therapy; Humans; Morphine; Naltrexone; Pain; Receptors, Opioid; Severity of Illness Index | 2010 |
Enhancing acupuncture by low dose naltrexone.
Topics: Acupuncture Therapy; Analgesics, Opioid; Cannabinoids; Chronic Disease; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Pain; Pain Management; Receptor Cross-Talk; Receptors, Cannabinoid | 2011 |
Influence of acute or repeated restraint stress on morphine-induced locomotion: involvement of dopamine, opioid and glutamate receptors.
Topics: Acute Disease; Animals; Benzazepines; Chronic Disease; Dizocilpine Maleate; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Antagonists; Male; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Restraint, Physical; Stress, Psychological; Sulpiride | 2002 |
Effects of naltrexone on spontaneous itch-associated responses in NC mice with chronic dermatitis.
Topics: Animals; Behavior, Animal; Chronic Disease; Dermatitis, Atopic; Female; Injections, Subcutaneous; Male; Mice; Mice, Inbred Strains; Naltrexone; Narcotic Antagonists; Pruritus; Skin | 2002 |
[Repeated 100 Hz TENS for the treatment of chronic inflammatory pain in rats: optimal parameters and possible neuro-chemical mechanisms].
Topics: Animals; Arthralgia; Arthritis, Experimental; Chronic Disease; Dynorphins; Naltrexone; Pain Threshold; Rats; Substance P; Transcutaneous Electric Nerve Stimulation | 1999 |
Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala.
Topics: Amygdala; Analgesics, Opioid; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Benzamides; Chronic Disease; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dynorphins; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Freund's Adjuvant; Guanosine 5'-O-(3-Thiotriphosphate); Injections, Intraventricular; Male; Maze Learning; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Narcotics; Pain; Pain Measurement; Piperazines; Protein Binding; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reaction Time; Sciatica; Somatostatin; Sulfur Isotopes; Time Factors; Tranquilizing Agents | 2006 |
Chronic pain-induced emotional dysfunction is associated with astrogliosis due to cortical delta-opioid receptor dysfunction.
Topics: Animals; Anxiety Disorders; Astrocytes; Brain Tissue Transplantation; Cells, Cultured; Cerebral Cortex; Chronic Disease; Culture Media, Conditioned; Disease Models, Animal; Gliosis; Gyrus Cinguli; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Neuralgia; Pain, Intractable; Peripheral Nervous System Diseases; Receptors, Opioid, delta; Sciatic Neuropathy; Stem Cells | 2006 |
Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Cell Survival; Chronic Disease; Glutathione; Liver; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Oxidative Stress; Pain; Signal Transduction | 2006 |
Effects of atypical anxiolytic N-phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats.
Topics: Acute Disease; Alcohol Drinking; Animals; Anti-Anxiety Agents; Chronic Disease; Dose-Response Relationship, Drug; Drinking; Drug Tolerance; Injections, Intraperitoneal; Male; Naltrexone; Narcotic Antagonists; Piperidines; Pyridines; Rats | 2007 |
Endogenous opioids modulate hepatocyte apoptosis in a rat model of chronic cholestasis: the role of oxidative stress.
Topics: Analgesics, Opioid; Animals; Apoptosis; Biological Factors; Cholestasis; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Hepatocytes; Liver; Naltrexone; Narcotic Antagonists; Oxidative Stress; Rats | 2007 |
Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Topics: Analgesics, Opioid; Animals; Chronic Disease; Dipeptides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; G(M1) Ganglioside; Hyperalgesia; Male; Mice; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Opioid Peptides; Receptors, Opioid, kappa; Substance Withdrawal Syndrome | 2007 |
Involvement of kappa opioid receptors in formalin-induced inhibition of analgesic tolerance to morphine in mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Chronic Disease; Drug Tolerance; Formaldehyde; Male; Mice; Morphine; Naltrexone; Oligonucleotides, Antisense; Pain; Pain Measurement; Pain Threshold; Receptors, Opioid, delta; Receptors, Opioid, kappa; Tail | 2007 |
Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors.
Topics: Acute Disease; Animals; Behavior, Animal; Benzylidene Compounds; Chronic Disease; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Heroin Dependence; Male; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Time Factors | 2008 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline | 2008 |
Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Amygdala; Analgesics, Non-Narcotic; Animals; Chronic Disease; Electric Stimulation; Electrophysiology; Emotions; Extinction, Psychological; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Naltrexone; Pain; Receptors, Opioid, kappa; Synaptic Transmission | 2009 |
Endogenous opioid peptide mediation of hypoalgesic response in long-term diabetic rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Chronic Disease; Diabetes Mellitus, Experimental; Endorphins; Enkephalin, Methionine; Half-Life; Hypoglycemic Agents; Insulin; Male; Naltrexone; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley | 1996 |
Evidence that spinal endogenous opioidergic systems control the expression of chronic pain-related behaviors in spinally injured rats.
Topics: Animals; Behavior, Animal; Chronic Disease; Cold Temperature; Female; Hyperalgesia; Injections, Spinal; Naltrexone; Narcotic Antagonists; Pain; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Self Mutilation; Somatostatin; Spinal Cord Injuries; Stress, Mechanical | 1998 |
Role of the kappa-opioid system in the attenuation of the morphine-induced place preference under chronic pain.
Topics: Animals; Chronic Disease; Conditioning, Psychological; Formaldehyde; Hindlimb; Inflammation; Male; Morphine; Naltrexone; Pain; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Reward; Time Factors | 1999 |
Paradoxical effects of intracerebroventricular low-dose opioid antagonists in SHR with chronic pain.
Topics: Analgesia; Animals; Arteries; Blood Pressure; Body Temperature; Body Weight; Brain; Chronic Disease; Hypertension; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Pain; Pain Threshold; Quaternary Ammonium Compounds; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 1999 |
Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.
Topics: Administration, Oral; Adult; Cholestasis; Chronic Disease; Female; Humans; Infusions, Intravenous; Naltrexone; Narcotic Antagonists; Pruritus; Substance Withdrawal Syndrome | 2000 |
Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment.
Topics: Animals; Avoidance Learning; Behavior, Animal; Chronic Disease; Conditioning, Psychological; Depression; Disease Models, Animal; Fear; Feeding Behavior; Male; Maze Learning; Naltrexone; Narcotic Antagonists; Opioid Peptides; Random Allocation; Rats; Rats, Wistar; Single-Blind Method; Stress, Psychological | 2000 |
Characterization of itch-associated responses of NC mice with mite-induced chronic dermatitis.
Topics: Animals; Attention; Chronic Disease; Dermatitis; Female; Histamine; Immunoglobulin E; Mice; Mice, Inbred Strains; Mites; Naltrexone; Narcotic Antagonists; Pruritus; Serotonin; Substance P | 2001 |
Motivational effects mu- and kappa-opioid agonists following acute and chronic restraint stress: involvement of dopamine D(1) and D(2) receptors.
Topics: Acute Disease; Animals; Behavior, Animal; Benzomorphans; Chronic Disease; Conditioning, Operant; Injections, Intraventricular; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stress, Psychological | 2002 |
Psychiatric implications of endorphin research.
Topics: Animals; Avoidance Learning; Behavior, Animal; Chronic Disease; Endorphins; Humans; Mental Disorders; Naloxone; Naltrexone; Rats; Receptors, Opioid; Schizophrenia | 1979 |
Psychopathology and mood during heroin use: acute vs chronic effects.
Topics: Acute Disease; Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emotions; Euphoria; Heroin; Heroin Dependence; Humans; Male; Methadone; Morphine; Motor Activity; Naloxone; Naltrexone; Psychopathology | 1976 |
Gilles de la Tourette's syndrome associated with chronic schizophrenia.
Topics: Adolescent; Chronic Disease; Hallucinations; Haloperidol; Humans; Male; Naltrexone; Schizophrenia, Paranoid; Tic Disorders; Tourette Syndrome | 1988 |
Treatment of chronic anorexia nervosa with opiate blockade.
Topics: Adolescent; Adult; Anorexia Nervosa; Chronic Disease; Female; Humans; Male; Naltrexone | 1987 |
Chronic stress, aging and morphine analgesia: chronic stress affects the reactivity to morphine in young mature but not old rats.
Topics: Age Factors; Aging; Analgesia; Analysis of Variance; Animals; Chronic Disease; Dose-Response Relationship, Drug; Male; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Stress, Physiological; Time Factors | 1985 |